Ignite Creation Date:
2024-05-05 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00443092
Status:
COMPLETED
Last Update Posted:
2012-08-03
First Post:
2007-03-02
Brief Title:
Efficacy of Proprietary Cherry Juice Blend in Osteoarthritis of the Knee
Sponsor:
CherryPharm
Organization:
CherryPharm
Study Overview
Official Title:
A Double Blind Cross-over Study of the Efficacy of a Proprietary Cherry Juice Blend in Osteoarthritis of the Knee
Status:
COMPLETED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this research study is to test the ability of a proprietary cherry juice blend to be helpful in the treatment of osteoarthritis OA of the knee
Detailed Description:
The primary objective is to determine if the proprietary tart cherry juice blend improves the pain and function in persons with knee osteoarthritis A secondary objective is to ascertain if the blend lowers serum uric acid
This is a prospective double blind placebo controlled cross-over study
The study will be performed in the Philadelphia VA Medical Center 1 South Rheumatology Clinic with patients meeting ACR criteria for Kellgren grade 2-3 knee osteoarthritis and 4-9 pain severity on a VAS Fifty patients will be studied with each having 5 visits Subjects will take either the proprietary cherry blend or placebo for 6 weeks and then switch WOMAC pain and function will be the primary outcome with acetaminophen use walking time and serum uric acid as secondary outcomes
This is a prospective double blind placebo controlled cross-over study
The study will be performed in the Philadelphia VA Medical Center 1 South Rheumatology Clinic with patients meeting ACR criteria for Kellgren grade 2-3 knee osteoarthritis and 4-9 pain severity on a VAS Fifty patients will be studied with each having 5 visits Subjects will take either the proprietary cherry blend or placebo for 6 weeks and then switch WOMAC pain and function will be the primary outcome with acetaminophen use walking time and serum uric acid as secondary outcomes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| VA MIRB ID 00981 | None | None | None |